A vaccine against MERS has shown promise in mouse models, potentially aiding the development of a vaccine against COVID-19.
Moderna has announced that the first participants have been dosed in a Phase I study of their mRNA candidate vaccine against SARS-CoV-2, the virus that causes COVID-19.
Take a look behind the scenes of a recent Future Virology editorial entitled, ‘An insight into dengue virus proteins as potential drug/vaccine targets’, as we ask author Muhammad Faheem about recent advances in understanding dengue proteins and where the next 5–10 years could take us.
In this blog, we review some of the main targets of universal vaccines and the key challenges to their successful implementation.
A mouse study has revealed that obesity may be one factor explaining the significant amount of variation in the influenza virus each year, likely due to an impaired interferon defense response.
The National Institute of Allergy and Infectious Diseases has stopped administering an experimental HIV vaccine in the South Africa HVTN 702 clinical trial, after an independent data and safety monitoring board has found that the vaccine is ineffective at preventing HIV infection.
Optimizing vaccine models for Streptococcus pneumoniae suggests that vaccine programs need to be tailored to target specific subgroups including age and geographical region.
Administering the BCG vaccine intravenously, as opposed to intradermally, could improve the efficacy of the immunization according to new research in macaque models.
Using animal models, researchers have discovered that antibodies can be coaxed into proliferating and targeting HIV.
In this interview, we speak to Jenn Edwards from the Abigail Wexner Research Institute (OH, USA) about her research using the primary human epithelial cell models to examine Neisseria gonorrhoeae infections, the potential for vaccination against gonorrhea and a possible host-targeted therapy for this infection.